Kornimate/medical-research-clean huggingface dataset:
tdln-sparing rt followed by pd-1 inhibitor maintenance therapy in locally advanced escc

Conditions: Esophageal Carcinoma; Radiotherapy; Immunotherapy

Summary: the goal of this clinical trial is to learn if tumor draining lymph nodes-sparing radiotherapy (tdln-sparing rt) followed by immunotherapy as maintenance therapy works to treat locally advanced esophageal squamous cell cancer in adults.


Eligibility criteria:
inclusion criteria: 1. written informed consent 2. aged 18 years or above 3. histologically confirmed esophageal squamous cell carcinoma 4. clinical stages t3-4n0m0 or txn+m0 or txnxm1 (only for supraclavicular lymph nodes) based on the 8th uicc-tnm classification 7. eastern cooperative oncology group(ecog) performance status: 0-1 8. life expectancy ≥3 months 9. adequate organ functions absolute neutrophil counts (anc) ≥1.5×109⁄l; hemoglobin (hb) ≥9g⁄dl; platelet (plt) ≥100×109⁄l; total bilirubin ≤1.5 upper limit of normal (uln); aspartate transaminase (ast) ≤2.5 uln; alanine aminotransferase (alt) ≤2.5 uln; creatinine ≤1.5 uln exclusion criteria: 1. esophageal perforation or hematemesis 2. any active autoimmune disease or a history of autoimmune disease (such as the following, but not limited to: autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, pituitary inflammation, vasculitis, nephritis, hyperthyroidism and hypothyroidism (effective hormone replacement therapy excepted)) and immunosuppressive agents or systemic hormonal therapy indicated within 28 days (for adverse events of chemoradiotherapy excepted). 3. previously received or receiving pd-1 antibody therapy or other immunotherapy against pd-1/pd-l1. 4. allergic to any of the ingredients in pd-1 inhibitors for injection. 5. uncontrolled heart diseases or clinical symptoms, such as: (1) new york heart association(nyha) class ii or higher heart failure; (2) unstable angina; (3) myocardial infarction within 1 year; (4)clinically significant arrhythmia requiring clinical intervention. 6. congenital or acquired immunodeficiency (such as hiv infection); active hepatitis b (hbv-dna≥104 copy number/ml) or hepatitis c (positive hepatitis c antibody, and hcv-rna is higher than the detection limit of the analytical method); active tuberculosis. 7. active infection or unexplained fever \>38.5 °c within 2 weeks before randomization (fever due to tumor excepted, according to investigator). patients with fertility reluctant to take contraceptive measures during the trial, or female patients pregnant or breastfeeding. 8. according to the investigator, other factors that may cause termination of the study. ie, other serious diseases (including mental illness) require combined treatment, family or social factors, which may affect the safety or the collection of trial data.
study of cc-5013 to evaluate safety, pharmacokinetics and effectiveness for japanese patients with symptomatic anemia associated with myelodysplastic syndrome with a del(5)(q31-33) abnormality.

Conditions: Myelodysplastic Syndromes

Summary: the purpose of this clinical experience study is to determine whether cc-5013 is safe and effective (to include studying the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body \[pharmacokinetics\]) in japanese subjects with low- or intermediate-1-risk mds (ipss risk categories) associated with a deletion 5(q31-33) abnormality and symptomatic anemia.


Eligibility criteria:
inclusion criteria: * must understand and voluntarily sign an informed consent form. * age ≥ 20 years at the time of signing the informed consent form. * must be able to adhere to the study visit schedule and other protocol requirements. * diagnosis of myelodysplastic syndrome (mds) that meets international prognostic scoring system (ipss) criteria for low- or intermediate-1-risk disease associated with a deletion 5(q31-33) abnormality * symptomatic anemia secondary to mds defined as:untransfused hb level \< 10.0 g/dl and a functional assessment of cancer therapy (fact)-anemia subscale score of ≤ 74 or transfusion dependent anemia exclusion criteria: * pregnant or lactating females. * any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study. * prior therapy with lenalidomide. * patients with any of the following laboratory abnormalities within 14 days of starting study drug: absolute neutrophil count (anc) \ 2.5 mg/dl aspartate aminotransferase (ast) or alanine aminotransferase (alt) \> 3.0 x upper limit of normal (uln)

Keywords: myelodysplastic syndromes lenalidomide
thymosin-α1 in cancer-related fatigue

Conditions: Cancer Related Fatigue; Quality of Life

Summary: cancer-related fatigue (crf) is a distressing, persistent, subjective sense of physical, emotional, and/or cognitive tiredness or exhaustion related to cancer or cancer treatment that is not proportion to recent activity and interferes with usual functioning. compared with general fatigue, crf have the characteristics of long duration and generally cannot alleviate by rest or sleep, serious impact on the patient's work, study, entertainment and family life, and thus greatly affect the recovery, self-care ability and life quality of patients. many dates showed that 70%\~100% of cancer patients experienced cancer-related fatigue.for cancer-related fatigue there is no good treatment and intervention, in recent years, many clinical trials are carried out; central nervous stimulant, such as methylphenidate; acupuncture, aerobic exercise. all those measures may have certain therapeutic effect for crf, but don't have exact evidences from massive rct to confirm. thymosin-α1 (t-α1), a synthetic 28-amino acid peptide with multiple biological activities primarily directed towards immune response enhancement, this drug is used for the treatment of hbv and hepatitis c virus (hcv) infections, and being developed for the treatment of non-small cell lung cancer (nsclc), hepatocellular carcinoma, aids and malignant melanoma. t-α1 is able to potentiate the action of cytokines and also reduce the hematological toxicity of cytotoxic drug therapy, such as cyclophosphamide, 5-fluorouracil, dacarbazine. in this studies, we want to demonstrated that the effectiveness of thymosin-α1 for cancer-related fatigue in cancer patients who undergo chemotherapy.


Eligibility criteria:
inclusion criteria: 1. men and women aged 18 years and older. 2. the life expectancy at least 6 months. 3. with a definite pathological diagnosis of cancer, and undergo chemotherapy. 4. patients who are willing to participate in the study. exclusion criteria: 1. thymosin-α1 allergy. 2. using the spirit excitement or stimulant drugs. 3. with brain metastasis or primary malignant brain tumors. 4. with mental disorders, such as suffering from dementia, delirium, obsessive-compulsive disorder, schizophrenia, epilepsy. 5. other specific causes of fatigue: such as anemia, thyroid function is low, insomnia, uncontrolled pain. 6. serious hrs cardiopulmonary function disorder. 7. women during pregnancy and lactation.
a novel unidirectional face mask during nppv in copd patients

Conditions: Chronic Obstructive Pulmonary Disease

Summary: the purpose of this study is to determine the feasibility, safety and efficacy of a unidirectional breathing mask (breathe in through the nose and out through the mouth or breathe in through the mouth and out through the nose) in copd patients with breathing difficulties requiring noninvasive positive pressure ventilation (nppv).


Eligibility criteria:
inclusion criteria: 1. acute hypercapnic respiratory failure as a result of an acute exacerbation of copd defined as paco2 \> 50 mmhg, with or without hypoxia, and a respiratory rate of greater than 25/min with the use of accessory muscles of respiration or abdominal paradox; 2. requiring nppv as assessed by the managing care team. exclusion criteria: 1. patients with facial deformity, heavy beard or moustache which prevents a good seal between the mask and the face; 2. patients who have claustrophobia and cannot wear the mask; 3. patients who are hemodynamically unstable; 4. patients who are disoriented and unable to cooperate with the study procedure; 5. dni or dnr status or patients in whom intubation is contraindicated; 6. patients who are currently intubated; 7. patients who recently (\< 6months) had an mi or stroke; 8. pregnant woman; there will be no exclusion based on gender, race or ethnicity.

Keywords: unidirectional mask nppv copd respiratory physiology
ability of ([18f]-av-45) pet scan to distinguish alzheimer's disease subjects from cognitively normal individuals

Conditions: Alzheimer's Disease

Summary: this study will evaluate the performance characteristics of a novel \[18f\] amyloid detection ligand (18f\]-av-45) with respect to its ability to distinguish patients with clinically-diagnosed probable alzheimer's disease from cognitively normal elderly subjects and to independently compare its diagnostic performance characteristics with the ability of \[11c\]pib to correctly categorize the same subjects. specific hypotheses 1. individuals with a clinical diagnosis of probable alzheimer's disease will have increased brain retention of \[18f\]-av-45 compared to cognitively normal elderly individuals. 2. there will be no clinically meaningful difference in the amyloid retention performance characteristics of \[18f\]-av-45 and \[l1c\]pib.

15 patients with a clinical diagnosis of probable alzheimer's disease and 15 cognitively normal elderly control subjects will receive both \[18f\]-av-45 and \[11c\]pib to compare the diagnostic performance characteristics of each amyloid ligand to distinguish ad from normal subjects. in addition to clinical diagnostic category, ligand retention will be evaluated with respect to measures of symptom severity and cerebrospinal fluid levels of amyloid and tau.

Eligibility criteria:
inclusion criteria: * normal subjects: mini-mental state examination (mmse) 27-30, clinical dementia rating (cdr) = 0, no symptoms of depression * alzheimer's subjects: mmse 18-26, cdr \>=0.5, university of pennsylvania alzheimer's disease center consensus diagnosis of probable ad, absence of abnormalities on mri exclusion criteria: * other neurological disease * evidence of mri abnormality * psychiatric disorder * alcohol abuse * clinically significant lab abnormalities * residence in nursing facility * participation in clinical trial with experimental medication in past 1 month

Keywords: amyloid imaging positron emission tomography 18f-av-45 florbetapir f 18 diagnostic imaging
task-oriented occupational therapy approach in chronic stroke: performance, balance, quality of life

Conditions: Chronic Stroke; Occupational Therapy; Occupational Balance; Upper Extremity

Summary: chronic stroke is a neurological disorder that leads to long-term disability and functional impairments in motor, sensory, cognitive, and speech functions, persisting beyond six months after the stroke incident. the purpose of this study was to investigate the effects of task- oriented occupational therapy intervention on occupational performance, occupational balance, and quality of life in individuals with chronic stroke. the study included 30 individuals with chronic stroke aged between 18 and 65, who were divided into two groups: the task-oriented occupational therapy intervention group (toot) (n=15) and the control group (n=15). the participants in the toot group received task-oriented occupational therapy intervention in 30-minute sessions, five days a week, for four weeks, while the control group received routine upper-extremity-based occupational therapy intervention in a hospital setting.


Eligibility criteria:
inclusion criteria: * aged 18-65 years old, * completed the acute phase of stroke * experienced ischemic and/or hemorrhagic stroke * had \<=21 scores of montreal cognitive assessment (moca) * had \<= 15 scores of the rivermead motor assessment (rma) * had a motor stage of the hand and upper extremity motor stage level 3 or higher of the brunnstrom stages of motor recovery * had scoring 2 or lower on the modified ashworth scale for muscle tone around the shoulder, elbow, and wrist were included into the study. exclusion criteria: * had an orthopedic problem affecting the upper extremity * had undergone surgery in the past 6 months * had a diagnosis related to a psychotic disorder.
auraia study : impact evaluation at 3 months follow-up of a brief motivational intervention in reducing alcohol consumption among adolescents aged 16-24 in pontchaillou hospital emergency department in rennes, france

Conditions: Alcohol Abuse, Episodic Drinking Behavior

Summary: the purpose of this study is to evaluate the effectiveness of a brief motivational intervention (bmi), in reducing alcohol consumption among patients with hazardous or harmful drinking admitted in emergency department (ed). patients aged 16 to 24 and who tested positive for blood alcohol content (bac) of 0.5g/l. or above are enrolled. patients receive either an information leaflet or an information leaflet plus a referral to a psychologist. bmi is provided by the psychologist. bmi consists in a first face-to-face interview (35-45 minutes) plus a telephone interview, at 1 and 2 months. minors' parents are also invited to attend the bmi session. if necessary, patients can be referred to relevant care and treatment services for alcohol misuse. in a simple blind, randomised controlled clinical trial of 280 patients, 140 patients are allocated to the treatment group and 140 to the control group. randomisation is stratified according to patient's age (16-17 or 18-24). opaque and sealed randomized envelops are used for randomisation. alcohol consumption is measured by self-report at 3 months. the principal criteria used to assess the reduction of alcohol use at 3 months follow-up is the number of alcoholic drinks in the last week. other events such as ed readmission, quarrels related to alcohol, drinking and driving, sexual intercourse without protection will also be assessed. it is the first clinical trial in france comparing these two interventions among young patients in ed with this design.

eligible patients are recruited by ed physicians. staff in ed involved in the study is provided with a teaching session on the importance of alcohol misuse and inclusion procedures. prior to enrolment, a written informed consent is requested from every patient. for patients under 18, a consent form is also requested from parent(s) or the legal tutor.

Eligibility criteria:
inclusion criteria: * men or women aged 16-24 attending ed services between thursday 10 pm and sunday 8 am * breathalyzer test with a blood alcohol content (bac) of 0.5g/l or above * ability to give consent * parental or legal tutor's consent is requested for patients under 18 exclusion criteria: * already enrolled in the study * current ed visit for attempted suicide patients * current ed visit for injured trauma patients * alcohol dependence requiring hospitalisation or referral to local treatment * current enrolment or request to enrol in substance abuse treatment program

Keywords: alcohol hazardous or harmful drinking emergency department (ed)
short-term glycemic control for reducing post-surgical complications

Conditions: Diabetes; Uncontrolled Diabtetes

Summary: perioperative dysglycemia-hyperglycemia, hypoglycemia, and glycemic variability-is associated with an increased risk for adverse outcomes. several studies have reported the association between elevated preoperative hba1c and postoperative complications. there are no studies that confirm that postponing elective surgery improves patient outcomes. likewise, no prospective trials have studied whether short-term glycemic control reduces postoperative complications and unnecessary patient delays in elective surgeries. consequently, we designed a randomized controlled trial to investigate the effects of short-term glycemic control before major abdominal surgery on postoperative morbidity and mortality.

despite the limitations of measurements of hba1c, guidelines for perioperative glycemic management suggest delaying elective surgery if hba1c exceeds certain levels (7-8.5%) (joshi et al., 2010; cpoc, 2022). however, no studies confirm that postponing elective surgery improves patient outcomes. likewise, no prospective trials have studied whether short-term glycemic control reduces postoperative complications and unnecessary patient delays in elective surgeries (duggan et al., 2017). consequently, we designed a randomized controlled trial to investigate the effects of short-term glycemic control before major abdominal surgery on postoperative morbidity and mortality. we hypothesize that in diabetic patients who are presenting for non-cardiac non-elective surgery and whose hba1c is ≥7.5% (≥58 mmol/mol), short-term glycemic control would improve outcome compared to standard-of-care, as measured with days-at-home at 30 postoperative days (dah-30). the current study aims to detect the value of short-term glycemic control in uncontrolled diabetic patients (preoperative hba1c ≥7.5% \[≥58 mmol/mol\]) for reducing postoperative morbidity and mortality. the patients in the preoperative anesthesia clinic will be randomized into one of the upcoming groups: 1. short-term glycemic control group: patients will be admitted to the hospital for 2-3 days before surgery. during this pilot study, patients will be admitted to the intermediate care unit to monitor and control preoperative blood glucose. we aim to maintain moderate glucose control (140 - 180 mg/dl) using basal-bolus insulin protocol plus correctional doses as needed. 2. standard-of-care group: patients will be admitted the day before surgery with the usual patient treatment. in both groups, diabetic drugs will be managed per local protocol.

Eligibility criteria:
inclusion criteria: * all adult diabetic patients (≥18 years) of either sex scheduled for major abdominal surgery (estimated operative time is \> 2 hours) with hb a1c ≥7.5% (58 mmol/mol). exclusion criteria: * patients \< 18 years * emergency surgery * elective surgery that can be postponed safely till glycemic control * hb a1c \< 7.5% * pregnant patients * patient refusal
awake prone positioning and oxygen therapy in patients with covid-19

Conditions: COVID; ARDS; Pneumonia

Summary: the prone position strategy for patients with acute respiratory distress syndrome (ards) is simple and cost-effective from the first description on its use in patients with acute respiratory failure to improve hypoxemia. different studies have investigated its safety and efficacy in various clinical settings, demonstrating that its early use in combination with non-invasive mechanical ventilation (niv) or high-flow oxygen therapy can reduce intubation rate and mortality in ards. in the coronavirus disease 2019 (covid-19) pandemic, high-value medicine and resource optimization are critical.

coronavirus disease 2019 (covid-19) is a pandemic that has significantly challenged health systems worldwide. due to the large number of infections around the world, the implementation of strategies to reduce the number of intubations and the need for invasive mechanical ventilation becomes important. in addition to the inability of the mexican health system to respond, patients under invasive ventilation have not had a favorable survival outcome. up to 97% mortality has been reported in patients requiring intubation. the exact cause of this poor prognosis is not yet known. early recognition of hypoxemic patients could help with the results. it seems reasonable in these patients to perform procedures to improve the clinical respiratory picture before intubation in less severe cases due to the aforementioned. prone patient placement during invasive mechanical ventilation is a widespread practice in the management of severe ards of other etiologies. currently, few attempts have been made to implement the prone position in patients who spontaneously ventilate with supplemental oxygen, high-flow nasal cannulas, or noninvasive mechanical ventilation. taking into account that it is a procedure that does not require additional infrastructure within the services and does not represent an additional cost for its implementation, it becomes a valuable tool in the context of covid-19 where intubation is associated with high mortality and in a additionally, there are mechanical ventilator deficits in most hospitals. this work has feasibility to be carried out because it will be carried out in critical areas that have equipment and trained personnel for it in the different shifts, in addition to having patients diagnosed with covid-19.

Eligibility criteria:
inclusion criteria * patient records with the following characteristics: * patients over 18 years of age * patients of both genders * patients diagnosed with covid-19 infection * patients admitted to hospital * complete file non-inclusion criteria • patients who do not decide to participate in the study exclusion criteria • files not found. elimination criteria * files with incomplete data * file with a voluntary discharge or transfer note.

Keywords: covid ards prone position
norfloxacin with itopride versus norfloxacin in secondary prophylaxis of spontaneous bacterial peritonitis

Conditions: Spontaneous Bacterial Peritonitis

Summary: norfloxacin versus norfloxacin with itopride in secondary prophylaxis of spontaneous bacterial peritonitis

comparative study of norfloxacin versus norfloxacin with itopride in secondary prophylaxis of spontaneous bacterial peritonitis

Eligibility criteria:
inclusion criteria: * cirrhotic patients with ascites who had previous episodes of sbp. exclusion criteria: * 1. allergy or contraindication for the used drugs. 2. recent antibiotics therapy in the previous 2 weeks. 3. patients with hepatocellular carcinoma or other neoplasia. 4. pregnant and lactating women.